Factors for Hematopoietic Toxicity of Carboplatin: Refining the Targeting of Carboplatin Systemic Exposure
Authors:
- Antonin SchmittASAntonin Schmitt
- Laurence GladieffLGLaurence Gladieff
- Céline M. LaffontCLCéline M. Laffont
- Alexandre EvrardAEAlexandre Evrard
- Jean-Christophe BoyerJBJean-Christophe Boyer
- Amélie LansiauxALAmélie Lansiaux
- Christine Bobin-DubigeonCBChristine Bobin-Dubigeon
- Marie-Christine Etienne-GrimaldiMEMarie-Christine Etienne-Grimaldi
- Michèle Boisdron-CelleMBMichèle Boisdron-Celle
- Mireille MousseauMMMireille Mousseau
- Frédéric PinguetFPFrédéric Pinguet
- Anne FloquetAFAnne Floquet
- 20 October 2010
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (30) , 4568-4574
Abstract
Purpose: Area under the curve (AUC) dosing is routinely carried out for carboplatin, but the chosen target AUC values remain largely empirical. This multicenter pharmacokinetic-pharmacodynamic (PK-PD) study was performed to determine the covariates involved in the interindividual variability of carboplatin hematotoxicity that should be considered when choosing individual target AUCs. Patients and Methods: Three hundred eighty-three patients received carboplatin as part of established regimens. A semi-physiologic population PK-PD model was applied to describe separately the time course of absolute neutrophil and platelet counts using NONMEM software. The plasma ultrafiltrable carboplatin concentration (CCarbo) was assumed to inhibit the proliferation of blood cell precursors through a linear model: drug effect = slope × CCarbo. The slope corresponds to the patients' sensitivity to carboplatin hematotoxicity. The relationships between the patients' sensitivity to the neutropenic or thrombopenic effects of carboplatin and various covariates, including associated chemotherapies, demographic, biologic, and pharmacogenetic data, were studied. Results: The sensitivity of carboplatin-induced thrombocytopenia decreased in the case of concomitant paclitaxel chemotherapy (slope decreased by 24%), whereas it increased with coadministration of etoposide and gemcitabine (slope increased by 45% and 133%, respectively). For neutropenia, the sensitivity increased when carboplatin was combined with other cytotoxics (slope increased by 76%). Conclusion: This study provides useful information to clinicians to better estimate the hematopoietic toxicity of carboplatin and thus choose more rationally carboplatin target AUCs as a function of pretreatment or concomitantly administered chemotherapies. For example, an AUC of 5 mg/mL · min is associated with a risk of grade 3 or 4 thrombocytopenia of 2% in combination with paclitaxel versus 38% with gemcitabine in a non-pretreated patient.Keywords
This publication has 15 references indexed in Scilit:
- A Universal Formula Based on Cystatin C to Perform Individual Dosing of Carboplatin in Normal Weight, Underweight, and Obese PatientsClinical Cancer Research, 2009
- Conditional Weighted Residuals (CWRES): A Model Diagnostic for the FOCE MethodPharmaceutical Research, 2007
- Model of Chemotherapy-Induced Myelosuppression With Parameter Consistency Across DrugsJournal of Clinical Oncology, 2002
- Phase I Trial, Including Pharmacokinetic and Pharmacodynamic Correlations, of Combination Paclitaxel and Carboplatin in Patients With Metastatic Non–Small-Cell Lung CancerJournal of Clinical Oncology, 1999
- Application of the area under the curve of carboplatin in predicting toxicity and efficacyCancer Treatment Reviews, 1998
- Prediction of Carboplatin Clearance From Standard Morphological and Biological Patient CharacteristicsJNCI: Journal of the National Cancer Institute, 1995
- Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer.Journal of Clinical Oncology, 1992
- Effectiveness of carboplatin, etoposide, and bleomycin combination chemotherapy in good-prognosis metastatic testicular nonseminomatous germ cell tumors.Journal of Clinical Oncology, 1991
- A novel pharmacodynamically based approach to dose optimization of carboplatin when used in combination with etoposide.Journal of Clinical Oncology, 1989
- Carboplatin dosage: prospective evaluation of a simple formula based on renal function.Journal of Clinical Oncology, 1989